Search
azacitidine; 5-azacytidine (Vidaza, Onureg)
Tradename: Vidaza (FDA-approved in 2004)
Indications:
- treatment of myelodysplastic syndrome [1]
- maintenance therapy for acute myeloid leukemia in 1st remission [2]
Mechanism of action:
- biomimetic, pyrimidine analog
Notes: Manufacturers: Pharmion (Vidaza), Bristol-Myers Squibb (Onureg).
General
pyrimidine antimetabolite; antimetabolite; pyrimidine analog
antineoplastic agent (chemotherapeutic agent)
Database Correlations
PUBCHEM correlations
References
- Prescriber's Letter 12(2): 2005
New Drugs Approved by the FDA in 2004
Detail-Document#: 210216
(subscription needed) http://www.prescribersletter.com
- Bankhead C
Year in Review: Acute Myeloid Leukemia.
MedPage Today November 29, 2020
https://www.medpagetoday.com/hematologyoncology/leukemia/89909
- Department of Veterans Affairs, VA National Formulary